LDL Targets for Treatment

Risk Stratification and LDL-C Goals

The European Society of Cardiology recommends an LDL-C goal of <1.8 mmol/L (<70 mg/dL) or a reduction of at least 50% if baseline LDL-C is between 1.8 and 3.5 mmol/L (70-135 mg/dL) for patients at very high cardiovascular risk 1, 2
Very high-risk category includes patients with documented cardiovascular disease (CVD), diabetes with target organ damage, severe chronic kidney disease, or a calculated SCORE risk ≥10% 1, 2
The European Society of Cardiology recommends an LDL-C goal of <2.6 mmol/L (<100 mg/dL) or a reduction of at least 50% if baseline LDL-C is between 2.6 and 5.2 mmol/L (100-200 mg/dL) for high-risk patients 1, 2
High-risk category includes patients with markedly elevated single risk factors, diabetes without target organ damage, or a calculated SCORE risk of ≥5% to <10% 2
The American Heart Association recommends an LDL-C goal of <2.6 mmol/L (<100 mg/dL) as a therapeutic option for moderately high-risk patients 3, 4
Traditional recommended goal is <3.0 mmol/L (<130 mg/dL) for moderately high-risk patients 3, 4
This category includes patients with 2+ risk factors and 10-year risk of 10-20% 3, 4
The European Society of Cardiology recommends an LDL-C goal of <3.0 mmol/L (<115 mg/dL) for patients with moderate risk 5

The European Society of Cardiology recommends statins as the first-line treatment to reach LDL-C goals 1
Use the highest recommended dose or highest tolerable dose to reach the goal 1
When LDL-lowering drug therapy is employed in high-risk or moderately high-risk persons, intensity should be sufficient to achieve at least a 30-40% reduction in LDL-C levels 3, 4
The American Heart Association recommends combining a fibrate or nicotinic acid with an LDL-lowering drug for patients with high triglycerides or low HDL-C 3, 6
When triglycerides are ≥200 mg/dL, non-HDL-C becomes a secondary target of therapy, with a goal 30 mg/dL higher than the identified LDL-C goal 3

The European Society of Cardiology recommends an LDL-C goal of <1.8 mmol/L (<70 mg/dL) for patients with type 2 diabetes and CVD or chronic kidney disease 2
Secondary goals include non-HDL-C <2.6 mmol/L (<100 mg/dL) and apoB <80 mg/dL for patients with type 2 diabetes and CVD or chronic kidney disease 2
The European Society of Cardiology recommends LDL-C lowering of at least 50% for all patients with type 1 diabetes and those with microalbuminuria/renal disease, regardless of baseline LDL-C 2
Treatment with statins is recommended for older adults with established CVD in the same way as for younger patients 1
Clinical trials confirm that older persons benefit from therapeutic lowering of LDL-C 4, 6
Patients with familial hypercholesterolemia (FH) should be treated with intensive-dose statin, often in combination with ezetimibe 2
FH should be suspected in patients with CHD before age 55 (men) or 60 (women), in subjects with relatives with premature CVD, tendon xanthomas, or severely elevated LDL-C (>5 mmol/L or 190 mg/dL in adults, >4 mmol/L or 150 mg/dL in children) 1, 2

Regular lipid assessments should be performed to monitor treatment efficacy 7
For patients on lipid-lowering therapy, more frequent monitoring is recommended 7
For patients with low-risk lipid values, assessments may be repeated every 2 years 7

Focusing solely on LDL-C without addressing other modifiable risk factors may lead to suboptimal outcomes 3, 4
Therapeutic lifestyle changes remain essential regardless of pharmacological therapy 3, 6

Small‑dense LDL particles more readily infiltrate the arterial wall, are retained, oxidize easily, and provoke inflammatory immune responses that drive atherogenesis. American Heart Association (AHA) scientific statement supports this mechanistic link. 8
Loss‑of‑function mutations in the PCSK9 and NPC1L1 genes lower LDL‑C by ~2–3 mg/dL and are associated with an ≈5 % reduction in lifetime coronary heart disease risk per 2.5 mg/dL LDL‑C decrease, demonstrating a causal relationship between modest LDL‑C lowering and reduced cardiovascular events. AHA genetic evidence review. 8

Initiating high‑intensity statin therapy (atorvastatin 40–80 mg daily or rosuvastatin 20–40 mg daily) achieves an average LDL‑C reduction of ~50 % in adult patients, providing the foundational LDL‑C lowering needed for plaque stabilization. American College of Cardiology (ACC) guideline. 9

Adding ezetimibe 10 mg daily to maximally tolerated statin therapy yields an additional 15–20 % LDL‑C reduction by inhibiting intestinal cholesterol absorption via NPC1L1, enhancing plaque‑stabilizing effects. ACC therapeutic recommendation. 8

For patients who remain above LDL‑C targets despite statin + ezetimibe, PCSK9‑inhibitors (evolocumab or alirocumab) provide a further 50–60 % LDL‑C reduction, enabling achievement of very low LDL‑C levels (<55 mg/dL) that are linked to more stable plaque morphology. ACC/ESC consensus. 8

LDL‑C percent reduction serves as a surrogate marker of therapeutic response and adherence, but the absolute LDL‑C level is the primary determinant of plaque stabilization; clinicians should therefore target specific LDL‑C thresholds rather than relative reductions alone. ACC guideline on treatment targets. 9
Individual variability in statin response is common; patients with sub‑optimal LDL‑C lowering may require intensified combination therapy to reach target levels. ACC statement on personalized lipid management. 9
Ongoing assessment of medication adherence every 3–12 months after achieving LDL‑C goals is essential for sustained cardiovascular risk reduction. AHA recommendation for longitudinal follow‑up. 10

Adoption of the DASH dietary pattern lowers LDL‑C by approximately 11 mg/dL compared with a typical Western diet, providing a non‑pharmacologic complement to drug therapy. ACC nutrition guideline. 11